AIMS: To examine the effects of nociceptin (NC) and endomorphin 1 (EM1) on electrical field stimulation (EFS)-induced contractions of the human vas deferens (hVD). METHODS: Concentration-response curves to NC and EM1 were constructed in the absence and in presence of peptidase inhibitors (PI). In some experiments a NC receptor antagonist, [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 [F/G], 10 microM) or naloxone (1 microM) were included. RESULTS: All data are mean(95%CI). In the presence of PI, NC inhibited twitches (Emax = 67(44,90)%; pEC50 = 7.28(6.95,7.61)). NC inhibition was sensitive to [F/G]. EM1 also inhibited twitches both in the absence (Emax = 82(73,91)% pEC50 = 7.07(6.92,7.22)) and presence (Emax = 83(76,90)%; pEC50 = 7.00(6.91, 7.09)) of PI. EM1 inhibition was sensitive to naloxone. CONCLUSIONS: These data suggest that hVD express NC and opioid receptors that inhibit neurogenic contractions.
AIMS: To examine the effects of nociceptin (NC) and endomorphin 1 (EM1) on electrical field stimulation (EFS)-induced contractions of the human vas deferens (hVD). METHODS: Concentration-response curves to NC and EM1 were constructed in the absence and in presence of peptidase inhibitors (PI). In some experiments a NC receptor antagonist, [Phe1psi(CH2-NH)Gly2]NC(1-13)NH2 [F/G], 10 microM) or naloxone (1 microM) were included. RESULTS: All data are mean(95%CI). In the presence of PI, NC inhibited twitches (Emax = 67(44,90)%; pEC50 = 7.28(6.95,7.61)). NC inhibition was sensitive to [F/G]. EM1 also inhibited twitches both in the absence (Emax = 82(73,91)% pEC50 = 7.07(6.92,7.22)) and presence (Emax = 83(76,90)%; pEC50 = 7.00(6.91, 7.09)) of PI. EM1 inhibition was sensitive to naloxone. CONCLUSIONS: These data suggest that hVD express NC and opioid receptors that inhibit neurogenic contractions.
Authors: G Calò; A Rizzi; G Bogoni; V Neugebauer; S Salvadori; R Guerrini; C Bianchi; D Regoli Journal: Eur J Pharmacol Date: 1996-09-05 Impact factor: 4.432
Authors: H Okawa; B Nicol; R Bigoni; R A Hirst; G Calo; R Guerrini; D J Rowbotham; D Smart; A T McKnight; D G Lambert Journal: Br J Pharmacol Date: 1999-05 Impact factor: 8.739
Authors: M Kitayama; J McDonald; T A Barnes; G Calo'; R Guerrini; D J Rowbotham; D G Lambert Journal: Naunyn Schmiedebergs Arch Pharmacol Date: 2007-06-28 Impact factor: 3.195